カレントテラピー　30-12　サンプル page 24/30

このページは カレントテラピー　30-12　サンプル の電子ブックに掲載されている24ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
治療薬解説bility of the DPP -4 inhibitor alogliptin combined with pioglitazone,in metformin-treated patients with type 2 diabetes. JClin Endocrinol Metab 97：1615-1622, 20129）DeFronzo RA：Current iss....

治療薬解説bility of the DPP -4 inhibitor alogliptin combined with pioglitazone,in metformin-treated patients with type 2 diabetes. JClin Endocrinol Metab 97：1615-1622, 20129）DeFronzo RA：Current issues in the treatment of type 2 diabetes.Overview of newer agents：where treatment is going.Am J Med 123（3 Suppl）：S38 -48, 201010）Hanefeld M：The role of pioglitazone in modifying the atherogeniclipoprotein profile. Diabetes Obes Metab 11：742 -756, 200911）Musso G, Cassader M, Rosina F, et al：Impact of currenttreatments on liver disease, glucose metabolism and cardiovascularrisk in non-alcoholic fatty liver disease（NAFLD）：a systematic review and meta-analysis of randomised trials.Diabetologia 55：885-904, 201212）Mazzone T, Meyer PM, Feinstein SB, et al：Effect of pioglitazonecompared with glimepiride on carotid intima -mediathickness in type 2 diabetes：a randomized trial. JAMA296：2572 -2581, 200613）Dormandy JA, Charbonnel B, Eckland DJ, et al；PROactiveinvestigators：Secondary prevention of macrovascularevents in patients with type 2 diabetes in the PROactiveStudy（PROspective pioglitAzone Clinical Trial In macro-Vascular Events）：a randomised controlled trial. Lancet366：1279-1289, 200514）Miyazaki Y, Mahankali A, Matsuda M, et al：Effect of pioglitazoneon abdominal fat distribution and insulin sensitivity intype 2 diabetic patients. J Clin Endocrinol Metab 87：2784 -2791, 200215）Karalliedde J, Buckingham R, Starkie M, et al；RosiglitazoneFluid Retention Study Group：Effect of various diuretictreatments on rosiglitazone -induced fluid retention. J AmSoc Nephrol 17：3482-3490, 200616）Rosenstock J, Inzucchi SE, Seufert J, et al：Initial combinationtherapy with alogliptin and pioglitazone in drug-naivepatients with type 2 diabetes. Diabetes Care 33：2406-2408,201017）Kaku K, Itayasu T, Hiroi S, et al：Efficacy and safety of alogliptinadded to pioglitazone in Japanese patients with type 2diabetes：a randomized, double -blind, placebo -controlledtrial with an open -label long -term extension study. DiabetesObes Metab 13：1028 -1035, 201118）Eliasson B, Moller - Goede D, Eeg - Olofsson K, et al：Lowering of postprandial lipids in individuals with type 2 diabetestreated with alogliptin and/or pioglitazone：a randomiseddouble -blind placebo -controlled study. Diabetologia55：915-925, 201219）Moritoh Y, Takeuchi K, Asakawa T, et al：Combining adipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazoneimproves glycaemic control, lipid profiles and beta-cell functionin db/db mice. Br J Pharmacol 157：415-426, 200920）White WB, Bakris GL, Bergenstal RM, et al：EXamination ofcArdiovascular outcoMes with alogliptIN versus standard ofcarE in patients with type 2 diabetes mellitus and acute coronarysyndrome（EXAMINE）：a cardiovascular safetystudy of the dipeptidyl peptidase 4 inhibitor alogliptin inpatients with type 2 diabetes with acute coronary syndrome.Am Heart J 162：620 -626.e1, 2011Current Therapy 2012 Vol.30 No.12130993